Mon, Oct 20, 2014, 5:42 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Cannabis Science, Inc. Message Board

  • jett.rich jett.rich Jan 12, 2012 9:49 PM Flag

    What are we waiting for here ... ?

    Is there something substantive which is on the stove which will result in palpable profits and drive up this PPS? Or is it pump press releases that CBIS has been firing off recently? Good to see press, but whats the result?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Todays price action is "what we are waiting for"....
      How do you like it now ?
      $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$

    • thats why they just gave forward guidence that they expect .02 ashare in Earnings in 2014...thats HUGE !!

    • and when it does get legalized...CBIS extracts will be flying off the Shelves without even having to get FDA trials. ...just like they are now in Colorado...
      and if you read the latest PR it says their Extracts will be available in California soon... so when California gets legalized their product will have HUGE SALES going forward >>>>>>

    • Look ahead for future clinical trials then FDA approval of their extracts.
      Remember a similar company GW pharma got 18 million from Otsuka Partner....CBIS could get a partner when Clinical trials are good.
      Also the closer we get to the Vote to legalize in California which we almost passed last time ...missed by some 8% of the vote...
      That would send the whole sector flying....
      Lots to look forward to...

      • 2 Replies to grni12c
      • Not to take wind out of sails here, but FDA approval will require quite a byzentine process, requiring 1st and foremost that the DOJ re-classify Cannabis as a Schedule 2 drug.

        I did a little searching here for the FDA process:

        http://www.fda.gov/drugs/resourcesforyou/consumers/ucm143534.htm

        the summarized version is bulleted below;

        Drug Review Steps
        Preclinical (animal) testing.
        An investigational new drug application (IND) outlines what the sponsor of a new drug proposes for human testing in clinical trials.
        Phase 1 studies (typically involve 20 to 80 people).
        Phase 2 studies (typically involve a few dozen to about 300 people).
        Phase 3 studies (typically involve several hundred to about 3,000 people).
        The pre-NDA period, just before a new drug application (NDA) is submitted. A common time for the FDA and drug sponsors to meet.
        Submission of an NDA is the formal step asking the FDA to consider a drug for marketing approval.
        After an NDA is received, the FDA has 60 days to decide whether to file it so it can be reviewed.
        If the FDA files the NDA, an FDA review team is assigned to evaluate the sponsor's research on the drug's safety and effectiveness.
        The FDA reviews information that goes on a drug's professional labeling (information on how to use the drug).
        The FDA inspects the facilities where the drug will be manufactured as part of the approval process.
        FDA reviewers will approve the application or issue a complete response letter.

        NOTE:

        After pre-clinical animal vivisection comes three rigorous phases:

        Phase 1 studies (typically involve 20 to 80 people).
        Phase 2 studies (typically involve a few dozen to about 300 people).
        Phase 3 studies (typically involve several hundred to about 3,000 people).

        ..........................................................
        This looks like a long long road.

      • Very true indeed!

 
CBIS
0.053+0.005(+11.58%)Oct 20 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.